SCHEMBL581092

SCHEMBL581092

COC(=O)N1CCC(C(=O)O)CC1Cc1ccc(F)c(F)c1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.44
OPRK1 P41145 5/20 0.43
BRD4 O60885 3/20 0.41
CREBBP Q92793 3/20 0.41
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
CA9 Q16790 2/20 0.39
CA12 O43570 1/20 0.39
SIGMAR1 Q99720 4/20 0.38
DRD4 P21917 2/20 0.38
TMEM97 Q5BJF2 2/20 0.38
KDM4E B2RXH2 2/20 0.38
DRD3 P35462 1/20 0.37
RAB9A P51151 1/20 0.37
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL587316 0.91 ALDH1A1 (0.47) ALDH1A1OPRK1SIGMAR1DRD4TMEM97
SCHEMBL581620 0.89 TACR1 (0.35) ALDH1A1OPRK1BRD4CREBBPCA1
SCHEMBL581759 0.89 NOTUM (0.40) OPRK1CA1CA2CA9CA12
SCHEMBL580834 0.87 NOTUM (0.41) ALDH1A1BRD4CREBBPCYP3A4CYP2D6
SCHEMBL582219 0.87 ALDH1A1 (0.43) ALDH1A1SIGMAR1KDM4ERAB9A
SCHEMBL582162 0.86 KMT2A (0.43) ALDH1A1BRD4CREBBPSIGMAR1RAB9A
SCHEMBL581154 0.85 CHIT1 (0.43) OPRK1
SCHEMBL581731 0.85 PSEN1 (0.36) ALDH1A1OPRK1BRD4CREBBPCA1
SCHEMBL3076755 0.85 ALDH1A1 (0.48) ALDH1A1OPRK1SIGMAR1DRD4TMEM97
SCHEMBL582790 0.85 ALDH1A1 (0.48) ALDH1A1OPRK1SIGMAR1DRD4TMEM97

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102459246-B Isoxazol-3 (2H) -one analogs as therapeutic agents ASTRAZENECA AB 2014-05-07 CN disclosed
US-8415378-B2 Isoxazol-3(2H)-one analogs as therapeutic agents ASTRAZENECA AB (SE) 2013-04-09 US disclosed
EP-2417131-A1 ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS AstraZeneca AB (SE) 2012-02-15 EP disclosed
WO-2010117323-A1 METHOD AND APPARATUS FOR PRODUCING HEAT ENERGY AND CARBON DIOXIDE ASTRAZENECA AB (SE) 2010-10-14 WO disclosed
US-20100261755-A1 ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS ASTRAZENECA AB (SE) 2010-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261755-A1 ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS NR4A3, CBR3, OXER1 ALDH1A1 2598/4885OPRK1 164/4885BRD4 208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.